<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3301">
  <stage>Registered</stage>
  <submitdate>16/09/2011</submitdate>
  <approvaldate>16/09/2011</approvaldate>
  <nctid>NCT01437787</nctid>
  <trial_identification>
    <studytitle>Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis</studytitle>
    <scientifictitle>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly</scientifictitle>
    <utrn />
    <trialacronym>JAKARTA</trialacronym>
    <secondaryid>2011-001897-25</secondaryid>
    <secondaryid>EFC12153</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hematopoietic Neoplasm</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SAR302503
Treatment: drugs - Placebo

Placebo Comparator: Placebo comparator - once daily X 28 days, orally, empty stomach, approximately same time each day

Experimental: SAR302503 400 mg - once daily X 28 days, orally, empty stomach, approximately same time each day

Experimental: SAR302503 500 mg - once daily X 28 days, orally, empty stomach, approximately same time each day


Treatment: drugs: SAR302503
Pharmaceutical form:capsule
Route of administration: oral

Treatment: drugs: Placebo
Pharmaceutical form:capsule
Route of administration: oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response Rate (RR), defined as the proportion of patients who have a =35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom Response Rate (SRR): Proportion of patients with =50% reduction from baseline to the end of Cycle 6 in the total symptom score. - This assessment will be conducted through the modified MFSAF diary, which will be completed during the week prior to Day 1 of each treatment cycle up to Cycle 6, and during the week prior to the end of Cycle 6.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.</outcome>
      <timepoint>approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PFS (progression free survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.</outcome>
      <timepoint>approximately 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients who have =25% reduction in volume of spleen size at end of Cycle 6, and confirmed 4 weeks thereafter.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of spleen response, measured by MRI (or CT scan in patients with contraindications for MRI.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical and laboratory events graded by the NCI CTCAE v4.03.</outcome>
      <timepoint>approximately 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Diagnosis of Primary Myelofibrosis (MF) or Post-Polycythemia Vera MF or Post-Essential
             Thrombocythemia MF, according to the 2008 World Health Organization and International
             Working Group of Myelofibrosis Research and Treatment (IWG-MRT) criteria.

          -  MF classified as high-risk or intermediate-risk level 2, as defined by modified
             IWG-MRT criteria (IPSS) (according to Cervantes F. et. al.; at screening).

          -  Enlarged spleen, palpable at least 5 cm below costal margin.

          -  At least 18 years of age.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at study entry.

          -  The following laboratory values within 14 days prior to the initiation of IMP or
             placebo:

          -  Absolute Neutrophil Count (ANC) =1.0 x 10exp9/L

          -  Platelet count =50 x 10exp9/L

          -  Serum creatinine =1.5 x Upper Limit of Normal (ULN)

          -  Serum amylase and lipase =1.5 x ULN</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Splenectomy.

          -  Any chemotherapy (eg, hydroxyurea), immunomodulatory drug therapy (eg, thalidomide,
             interferon-alpha), Anagrelide, immunosuppressive therapy, corticosteroids &gt;10 mg/day
             prednisone or equivalent, or growth factor treatment (eg, erythropoietin), or hormones
             (eg, androgens, danazol) within 14 days prior to initiation of IMP or placebo;
             darbepoetin use within 28 days prior to initiation of IMP or placebo. Patients who
             have had exposure to hydroxyurea (eg, hydrea) in the past may be enrolled into the
             study as long as it has not been administered within 14 days prior to initiation of
             IMP or placebo.

          -  Major surgery within 28 days or radiation within 6 months prior to initiation of IMP
             or placebo.

          -  Prior treatment with a Janus Kinase 2 (JAK2) inhibitor.

          -  Known active (acute or chronic) Hepatitis A, B, or C; and hepatitis B and C carriers

          -  AST or ALT =2.5 x ULN

          -  Total Bilirubin:

          -  Exclude if =3.0 x ULN

          -  Patients with total bilirubin between 1.5-3.0 x ULN must be excluded if the direct
             bilirubin fraction is =25% of the total

          -  Prior history of chronic liver disease (eg, chronic alcoholic liver disease,
             autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis,
             hemachromatosis, non-alcoholic steatohepatitis [NASH])

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>289</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036001 - Box Hill</hospital>
    <hospital>Investigational Site Number 036005 - Herston</hospital>
    <hospital>Investigational Site Number 036003 - Randwick</hospital>
    <hospital>Investigational Site Number 036004 - Tweed Heads</hospital>
    <hospital>Investigational Site Number 036002 - Wodonga</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Jau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio De Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saint John</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 01</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Györ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemét</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Galway</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Varese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Bundang-Gu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Klaipeda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Queretaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Brzozow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Petrozavodsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St.-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Parktown</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uddevalla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle Upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

        -  To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503
           (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen
           volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in
           patients with contraindications for MRI).

      Secondary Objectives:

        -  To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as
           measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary.

        -  To evaluate the Overall Survival of patients treated with either 400 mg/day or 500
           mg/day of IMP as compared to placebo.

        -  To evaluate the Progression Free Survival of patients treated with either 400 mg/day or
           500 mg/day of IMP as compared to placebo.

        -  To evaluate the durability of splenic response.

        -  To evaluate the safety of IMP.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01437787</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>